OPKO Health reports Q1 revenue decline to $124.2M, narrows loss, initiates two Phase 1 trials

Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 revenue fell 17% YoY to $124.2M (from $149.9M) due to 2025 BioReference asset sale; operating loss improved 24% to $51.0M from $67.2M, net loss per share narrowed to $0.07 from $0.10

  Exhibit 99.1 verify on EDGAR →
• high

  Reaffirmed FY 2026 revenue guidance of $530-560M and provided Q2 guidance of $127-132M, implying sequential growth and acceleration through year-end

  Exhibit 99.1 verify on EDGAR →
• medium

  Initiated Phase 1 trial for MDX2301, a BARDA-funded tetravalent COVID-19 antibody targeting all known SARS-CoV-2 variants; completed first dose cohort in healthy and high-risk immune-impaired adults

  Exhibit 99.1 verify on EDGAR →